ACRP-CP Dumps Special Discount for limited time Try FOR FREE
ACRP-CP Dumps for success in Actual Exam Mar-2026]
NEW QUESTION # 67
Upon receipt of temperature-controlled IP, the study staff noticed the IP incurred a temperature excursion during transport. What should the staff do NEXT?
- A. Register IP in IWRS and continue with subject allocation.
- B. Quarantine IP without registering in IWRS and request replacement from sponsor.
- C. Dispose of IP and request replacement from sponsor.
- D. Register IP in IWRS, quarantine and notify sponsor of the excursion.
Answer: D
Explanation:
If a temperature-controlled IP has experienced a temperature excursion during transport, the appropriate action is to register the IP in the Interactive Web Response System (IWRS), quarantine it to prevent use, and immediately notify the sponsor. This procedure ensures that the IP is not used until the sponsor evaluates its stability and suitability.
GCP guidelines state that any IP affected by a temperature excursion should be quarantined and reported to the sponsor for evaluation.
"Upon identification of a temperature excursion, the IP must be quarantined and reported to the sponsor to determine its usability." Objectives:
* Maintain IP integrity and compliance with storage conditions.
* Follow protocol for managing temperature excursions.
NEW QUESTION # 68
Confidentiality and privacy rules for protection of human subjects at research sites are determined by the:
- A. Applicable site SOPs
- B. Sponsor
- C. PI
- D. Applicable regulatory authorities
Answer: D
Explanation:
The confidentiality and privacy rules protecting human subjects in clinical research are established by applicable regulatory authorities, such as the FDA or EMA, and must be followed by all research sites. These regulations ensure that participants' personal data are handled securely and ethically.
GCP guidelines mandate compliance with local, national, and international regulations regarding data confidentiality and privacy.
"Confidentiality and privacy protections are determined by applicable regulatory authorities and must be adhered to by all study sites." Objectives:
* Protect participant privacy.
* Ensure compliance with data protection regulations.
NEW QUESTION # 69
The coding system for a double-blind clinical trial is accessible by the:
- A. Regulatory authority
- B. Sponsor
- C. IRB/IEC
- D. PI
Answer: B
Explanation:
The sponsor is typically responsible for maintaining the code that links the treatment assignment to participants in a double-blind clinical trial. The code is securely maintained and is only accessible in cases where unblinding is necessary for safety reasons. This process helps to preserve the integrity of the study while allowing for emergency unblinding if needed.
GCP guidelines state that the sponsor should maintain the blind unless unblinding is necessary due to safety concerns or regulatory requirements.
"The sponsor maintains the randomization code and ensures that unblinding occurs only when necessary, to protect the study's integrity." Objectives:
* Maintain the integrity of double-blind trials.
* Allow controlled access to randomization codes.
NEW QUESTION # 70
A printed, optical, or electronic document designed to record all of the protocol-required information and is transmitted to the sponsor is called a:
- A. Worksheet.
- B. CRF.
- C. PRO.
- D. Source document.
Answer: B
Explanation:
A Case Report Form (CRF) is a tool used in clinical trials to collect data as specified by the protocol. It is a printed, optical, or electronic document designed to record all protocol-required information for each trial subject. CRFs are crucial for ensuring that the data collected during the trial is accurate, complete, and consistent with the protocol.
This answer follows GCP guidelines, which describe CRFs as essential documents for capturing and transmitting study data to the sponsor.
"A Case Report Form (CRF) is a printed, optical, or electronic document specifically designed to record all protocol-required information to be reported to the sponsor on each trial subject." Objectives:
* Understand the role of CRFs in clinical trials.
* Ensure accurate and complete data collection.
NEW QUESTION # 71
A deferred consent can take place in which of the following situations?
- A. Only when the PI approves such a consent process immediately prior to patient enrollment, regardless of the situation being classed as emergency.
- B. Only when the PI approves such a consent process, regardless of the emergency situation described in the protocol.
- C. In an emergency situation only, when this process is described in the protocol and has received permission from the ethics committee.
- D. In an emergency situation only, even when this process is not described in the protocol, but the sponsor approves the consent process.
Answer: C
Explanation:
Deferred consent is permissible in emergency situations where immediate intervention is necessary and obtaining prior consent is not feasible. However, this practice must be explicitly described in the protocol and approved by the ethics committee. This ensures that the rights of patients are protected even in urgent circumstances.
GCP guidelines emphasize that deferred consent is only allowed when pre-approved by the ethics committee as part of the protocol for emergency interventions.
"In emergencies, deferred consent is permitted only if outlined in the protocol and approved by the ethics committee, ensuring compliance with ethical standards." Objectives:
* Protect patient rights in emergency research.
* Ensure ethical approval for deferred consent.
NEW QUESTION # 72
A PI on a study is a regular member of the IRB/IEC. Which of the following statements is TRUE regarding their participation in the IRB/IEC discussion and deliberation?
- A. They cannot be the PI on the clinical study due to conflict of interest.
- B. They must recuse themselves from the meeting given their dual roles as IRB/IEC member and PI.
- C. They can attend the meeting and can vote/provide opinion on whether to approve the study.
- D. They can attend the meeting, but should not vote/provide opinion on whether to approve the study.
Answer: B
Explanation:
If a PI is also a member of the IRB/IEC, they must recuse themselves from the meeting when their own study is being reviewed to avoid conflicts of interest. This practice preserves the objectivity and impartiality of the IRB/IEC's decisions.
The answer is verified based on IRB/IEC operational guidelines, which mandate that members with potential conflicts recuse themselves from discussions and voting.
"To maintain objectivity, IRB/IEC members who have a conflict of interest related to a study must recuse themselves from the review and decision-making process." Objectives:
* Maintain impartiality in IRB/IEC decisions
* Prevent conflicts of interest in clinical trial approval
NEW QUESTION # 73
A clinical trial is conducted to measure the effectiveness of music therapy to reduce anxiety in intensive care unit patients. Patients are randomly assigned to receive headphones with music of their choice or headphones with white noise. The group receiving the white noise headphones is considered which type of control group?
- A. No treatment
- B. Active control
- C. Alternate dose
- D. Placebo
Answer: D
Explanation:
In this trial, the white noise group acts as a placebo control. While they are receiving an intervention (white noise), it is not the active therapeutic intervention (music therapy) being tested. Placebo controls help in assessing the effect of the active intervention by comparing it to a neutral or non-therapeutic alternative.
GCP guidelines state that a placebo control is a neutral intervention used to compare the effects of an active treatment.
"A placebo group is one that receives a neutral intervention, used to measure the efficacy of the active intervention by comparison." Objectives:
* Differentiate between active and placebo control groups.
* Evaluate therapeutic efficacy objectively.
NEW QUESTION # 74
A site is starting up a Phase III trial. They have received IRB/IEC approval and have scheduled the SIV. The site cannot begin enrolling subjects until:
- A. The site receives approval from the medical monitor to begin enrolling.
- B. A signed clinical trial agreement between the site and sponsor is in place.
- C. The DSMB meets and the first DSMB meeting report has been issued.
- D. The CRA has performed source document review and verification at the site.
Answer: B
Explanation:
Before a clinical trial site can begin enrolling participants, there must be a signed clinical trial agreement (CTA) between the site and the sponsor. This agreement outlines the responsibilities, financial arrangements, and expectations between both parties, ensuring that the trial is conducted in compliance with regulatory and ethical standards.
GCP guidelines require that a formal agreement be in place before trial initiation to protect the rights and obligations of both the sponsor and the site.
"Before subject enrollment can commence, the sponsor and site must finalize a clinical trial agreement, establishing legal and ethical commitments." Objectives:
* Ensure proper contractual arrangements before trial initiation.
* Protect legal rights and obligations of involved parties.
NEW QUESTION # 75
The sponsor must report a serious unexpected AE to the regulatory authorities within a maximum of:
- A. 8 calendar days
- B. 7 calendar days
- C. 30 calendar days
- D. 15 calendar days
Answer: D
Explanation:
The sponsor is required to report serious unexpected adverse events (SAEs) to the regulatory authorities within 15 calendar days from the date of awareness. This reporting period is mandated to ensure that any new safety information that may affect the risk/benefit profile of the investigational product (IP) is promptly communicated, thereby protecting participant safety.
GCP guidelines specify that serious, unexpected, and related AEs must be reported to regulatory authorities within 15 days of being known to the sponsor.
"Serious unexpected adverse reactions that may affect the safety profile of the IP must be reported within 15 calendar days to the regulatory authorities." Objectives:
* Ensure timely reporting of safety information.
* Protect the safety of trial participants.
NEW QUESTION # 76
Who is responsible to ensure training for key staff members unable to attend the site initiation visit?
- A. Investigator
- B. Coordinator
- C. Sponsor
- D. Monitor
Answer: A
Explanation:
The Principal Investigator (PI) is responsible for ensuring that all site staff involved in the study are adequately trained, even if they were unable to attend the Site Initiation Visit (SIV). This responsibility includes organizing training sessions or providing relevant training materials to maintain consistency and compliance with study protocols.
According to GCP guidelines, the PI must ensure that all staff members involved in the trial are adequately informed and trained on their specific responsibilities.
"The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions." Objectives:
* Maintain consistent training for all clinical staff.
* Ensure compliance with study procedures.
NEW QUESTION # 77
The investigator/institution should permit:
- A. Monitoring and inspection by the sponsor, and auditing by the appropriate regulatory authority(ies).
- B. Monitoring and inspection by the appropriate regulatory authority(ies), and auditing by the sponsor.
- C. Monitoring and auditing by the appropriate regulatory authority(ies), and inspection by the sponsor.
- D. Monitoring and auditing by the sponsor, and inspection by the appropriate regulatory authority(ies).
Answer: B
Explanation:
The investigator and institution must allow both monitoring and inspection by the appropriate regulatory authorities and auditing by the sponsor. This dual oversight ensures that the trial complies with regulatory standards and sponsor requirements, thereby maintaining the integrity and validity of the data.
GCP guidelines specify that regulatory authorities have the right to inspect, while sponsors typically conduct audits to verify compliance and data quality.
"The institution should permit monitoring and inspection by regulatory authorities and auditing by the sponsor to ensure compliance with GCP and protocol adherence." Objectives:
* Facilitate monitoring and inspection for compliance.
* Ensure trial data integrity and quality assurance.
NEW QUESTION # 78
The inclusion and exclusion criteria are in place so all subjects are:
- A. Healthy and willing to complete the clinical trial.
- B. Ethically vulnerable and patients with the disease under study.
- C. Patients with the disease under study and will not have any adverse events.
- D. Medically appropriate and protected from ethical vulnerability.
Answer: D
Explanation:
Inclusion and exclusion criteria are designed to ensure that participants are medically appropriate for the study and are not ethically vulnerable. This reduces risks to subjects and ensures that the collected data accurately reflects the target population.
The answer follows GCP principles that emphasize participant safety and data validity through well-defined inclusion/exclusion criteria.
"Inclusion and exclusion criteria are crucial for ensuring the safety of participants and the scientific validity of study results." Objectives:
* Ensuring participant safety.
* Maintaining ethical standards in clinical research.
NEW QUESTION # 79
Who must be blinded in a double-blind study in order to prevent bias?
- A. Pharmacist
- B. Subject
- C. Data entry staff
- D. IRB/IEC
Answer: B
Explanation:
In a double-blind study, both the participant (subject) and the investigator (or clinical staff administering the treatment) are blinded. This approach minimizes bias in treatment administration and outcome assessment.
Blinding the subject ensures that their responses are not influenced by their knowledge of the treatment they are receiving.
According to GCP guidelines, double-blinding is essential to eliminate both participant and investigator bias, ensuring objective trial results.
"Double-blind studies ensure that neither the participant nor the investigator knows which intervention is being administered, thereby minimizing bias." Objectives:
* Maintain the integrity of the study by preventing bias.
* Enhance the validity of trial outcomes.
NEW QUESTION # 80
All site financial matters pertaining to a trial are listed in what document?
- A. Informed consent form
- B. Financial disclosure
- C. Protocol
- D. Signed contract
Answer: D
Explanation:
All financial agreements, including compensation, budgeting, and payment terms related to the conduct of a clinical trial, are documented in the signed contract between the sponsor and the site. This contract outlines the financial responsibilities and ensures transparency and compliance.
GCP guidelines stipulate that financial matters related to the conduct of a trial are to be formally documented in contractual agreements.
"The financial aspects of a clinical trial must be outlined in the signed agreement between the sponsor and the site, ensuring clear understanding of compensation and obligations." Objectives:
* Ensure financial transparency and accountability.
* Maintain compliance with contractual obligations.
NEW QUESTION # 81
Which of the following would the sponsor need to do FIRST to set up an effective clinical trial quality management system (QMS)?
- A. Determine the quality tolerance limits for data transcription errors.
- B. Perform a periodic review to see if the quality methods are effective and relevant.
- C. Identify critical processes and data during protocol development.
- D. Train the research coordinator on the required study assessments schedule.
Answer: C
Explanation:
The first step in establishing a robust quality management system (QMS) is to identify critical processes and data during protocol development. This step ensures that quality objectives are clear and that monitoring and quality control efforts are focused on the most significant aspects of the study. By understanding critical data points and processes early, the sponsor can design a more effective QMS to manage risks.
GCP guidelines emphasize identifying critical data and processes at the earliest stages to develop a risk-based quality management approach.
"Identification of critical data and processes at the protocol development stage is essential for designing an effective quality management system." Objectives:
* Establish quality oversight from the start.
* Implement a risk-based monitoring approach.
NEW QUESTION # 82
Which entity has ultimate responsibility over the conduct of the multi-center clinical trial?
- A. Sponsor-Investigator
- B. Regulatory authority
- C. CRO
- D. IRB/IEC
Answer: A
Explanation:
In a multi-center clinical trial, the Sponsor-Investigator holds ultimate responsibility for the overall conduct of the study. This includes ensuring compliance with the protocol, maintaining data integrity, and overseeing all participating sites. The Sponsor-Investigator must ensure that each site follows the same procedures and standards to maintain consistency across the trial.
According to GCP guidelines, the Sponsor-Investigator must take responsibility for all aspects of a multi- center trial, including site coordination and data management.
"The Sponsor-Investigator assumes ultimate responsibility for the conduct of a multi-center clinical trial, ensuring protocol compliance and data consistency." Objectives:
* Maintain accountability across multi-center sites.
* Ensure uniformity in trial conduct.
NEW QUESTION # 83
A study has been closed for two years after the last approval of a marketing application of an IP. No additional applications are pending and there are no further developments planned for the IP. Which of the following statements is the BEST course of action regarding the destruction of the essential documents?
- A. The site should contact the sponsor and receive verbal notification they are no longer needed andthe essential documents may be destroyed.
- B. The site may proceed with the destruction of the essential documents.
- C. The site should retain the essential documents longer to meet the regulatory requirements.
- D. The site should contact the sponsor and receive written notification prior to destruction that the essential documents are no longer needed.
Answer: D
Explanation:
Before destroying any essential documents, the site must obtain written confirmation from the sponsor that these documents are no longer needed. This ensures compliance with regulatory requirements, as some countries may require document retention for longer periods, even after study closure and marketing approval.
GCP guidelines state that the sponsor must confirm in writing that essential documents can be destroyed after ensuring compliance with local regulations.
"Before destroying essential documents, written confirmation from the sponsor is required to ensure compliance with regulatory retention policies." Objectives:
* Maintain compliance with document retention regulations.
* Prevent premature destruction of essential trial records.
NEW QUESTION # 84
In order to conduct open-label, parallel group clinical trials according to sound scientific principles, which of the following design elements should be included?
- A. Blinding
- B. Randomization
- C. Placebo-controlled
- D. Privacy controls
Answer: B
Explanation:
Randomization is a key element in open-label, parallel group clinical trials to reduce selection bias and ensure that participant allocation is not influenced by investigators. Despite the absence of blinding in open-label studies, randomization maintains the validity and reliability of the results by evenly distributing confounding factors between groups.
GCP guidelines recommend randomization as a core element in clinical trial design to ensure unbiased allocation of participants.
"Randomization in parallel group trials helps minimize selection bias and ensures the comparability of intervention groups." Objectives:
* Maintain scientific rigor through randomization.
* Minimize selection bias in clinical studies.
NEW QUESTION # 85
A serious unexpected ADR is one:
- A. Severity and nature of the reaction is consistent with protocol.
- B. Where the severity of the reaction is not consistent with IB.
- C. That does not need to be reported to the IRB/IEC.
- D. That results in the death of the subject.
Answer: B
Explanation:
A serious unexpected adverse drug reaction (ADR) is characterized by an event that is not consistent with the information provided in the Investigator's Brochure (IB). Such reactions may indicate new risks associated with the investigational product and warrant immediate reporting to the sponsor and regulatory authorities.
This answer follows the ICH E6(R2) GCP guidelines, which specify the criteria for reporting serious and unexpected adverse events.
"An unexpected adverse drug reaction is one whose nature or severity is not consistent with the applicable product information (e.g., IB)." Objectives:
* Understanding classification of ADRs
* Ensuring timely and accurate reporting of unexpected events
NEW QUESTION # 86
A representative from a regulatory authority shows up unannounced at a research site. After confirming their credentials, the representative requested to view the entire records, including identifiable information, from study XYZ that was closed out. Which of the following should the site personnel do next?
- A. Deny the request until the sponsor approves.
- B. Redact subject identification for privacy protection.
- C. Consult with the IRB/IEC first.
- D. Allow access to the entire records.
Answer: D
Explanation:
Regulatory authorities have the legal right to inspect clinical trial records, including identifiable information, even if the study has been closed out. After verifying the inspector's credentials, the site personnel must grant access to all requested documents to ensure compliance with regulations.
According to GCP guidelines, regulatory authorities have the right to access trial-related documents and data during inspections.
"Investigators must grant access to study records when requested by regulatory authorities as part of their inspection rights." Objectives:
* Ensure compliance with inspection requirements.
* Maintain transparency with regulatory authorities.
NEW QUESTION # 87
A study protocol must contain which of the following elements?
- A. Data management plan
- B. Chemical structure of the IP
- C. Participant reimbursement details
- D. Description of statistical methods
Answer: D
Explanation:
A clinical study protocol must include a clear description of the statistical methods to be used in analyzing the collected data. This ensures that the analysis plan is predefined, unbiased, and statistically sound. The statistical methodology must address how the primary and secondary endpoints will be evaluated.
GCP guidelines require that the protocol clearly outlines statistical methods to ensure accurate and unbiased analysis of trial data.
"The protocol should include a detailed description of the statistical methods employed to ensure the validity of the trial results." Objectives:
* Maintain transparency in data analysis.
* Ensure scientific rigor in evaluating study outcomes.
NEW QUESTION # 88
Which document confirms the PI's agreement to permit auditing at the study site?
- A. ICF
- B. Protocol
- C. Delegation Log
- D. IB
Answer: A
Explanation:
The Informed Consent Form (ICF) typically includes a statement indicating that the participant's records may be reviewed by monitors, auditors, and regulatory authorities. This ensures transparency and compliance with regulatory requirements, allowing for audits and inspections when necessary.
This answer follows GCP guidelines which specify that the ICF should include consent for audits and inspections to protect subject confidentiality while ensuring data integrity.
"The ICF must include a statement allowing access to trial data for monitoring, auditing, and regulatory inspection purposes." Objectives:
* Ensure informed consent for data access.
* Facilitate compliance with auditing requirements.
NEW QUESTION # 89
Who takes responsibility for initiating a clinical trial?
- A. Sponsor
- B. Investigator
- C. CRO
- D. IRB/IEC
Answer: A
Explanation:
The sponsor is responsible for initiating a clinical trial. This involves developing the protocol, securing funding, selecting study sites, and obtaining regulatory approvals. The sponsor also oversees the conduct of the trial to ensure compliance with GCP and regulatory requirements.
According to GCP guidelines, the sponsor is the entity that initiates, manages, and finances the clinical investigation.
"The sponsor is responsible for initiating, managing, and financing the clinical trial, including protocol development and site selection." Objectives:
* Understand the sponsor's role in trial initiation.
* Ensure compliance from the outset of the study.
NEW QUESTION # 90
......
Accurate ACRP-CP Answers 365 Days Free Updates: https://pdfpractice.actual4dumps.com/ACRP-CP-study-material.html